Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 5.23B 400M 2025-12
Bristol-Myers Squibb USD 10.21B 5.52B 2025-12
Galectin Therapeutics USD 25.6M 2.04M 2024-06
Gilead Sciences USD 7.33B 2.19B 2025-09
Immunic USD 35.13M 20.18M 2025-09
Incyte USD 3.58B 650.78M 2025-12
Merck USD 18.17B 10.16B 2025-09